Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAIP pseudogene 3 (NAIPP3) is annotated as a **pseudogene** related to the NLR family apoptosis inhibitory protein (NAIP) gene cluster. Unlike the canonical "NLR family apoptosis inhibitory protein" (NAIP/BIRC1), which encodes a functional protein that suppresses apoptosis and participates in innate immune signaling, NAIPP3 does not produce a functional protein product due to truncations or deletions typical of pseudogenes. The human NAIP locus includes multiple copies: one full-length (protein-coding) and several truncated pseudogenes; these are a result of complex duplication events on chromosome 5q13[1][3][4]. No biological, disease, or therapeutic function is attributed to NAIPP3 itself; any such roles are associated with the functional NAIP gene. It is not a known therapeutic target, and its clinical or pharmacological significance is negligible[1][2][3][4]. **Key points:** - NAIPP3 is a **non-coding pseudogene** derived from the NAIP gene family[3][4]. - It does **not produce an active protein**, nor is it a therapeutic or pharmacological target. - The true biological and clinical relevance lies with the *functional* NAIP gene, not its pseudogene copies. - If the intention was to refer to the functional protein, the correct term is "NLR family apoptosis inhibitory protein" (abbreviation: NAIP or BIRC1)[1][2][3][4]. **Summary of possible issues:** - **is_incorrect:** true. The query refers to a pseudogene, not a protein or functional target. - **is_target:** false. Pseudogenes like NAIPP3 are not therapeutic targets. - **Use functional "NAIP" for target-based structured data**—not NAIPP3.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NLR family apoptosis inhibitory protein pseudogene 3 (NAIPP3).